Compare BridgeBio Pharma Inc (BBIO) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs D Wave Quantum Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while D Wave Quantum Inc trades at $20.36 (market cap $7.52B). The key difference: BridgeBio Pharma Inc is far larger — about 2.2× D Wave Quantum Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | QBTS | |
|---|---|---|
Market Cap | $16.61B | $7.52B |
Sector | Health | Technology |
52-Week High | $90.17 | $44.78 |
52-Week Low | $47.29 | $12.98 |
Enterprise Value | $18.16B | $7.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
D-Wave Quantum (QBTS) trades at $20.74, up 6.85% today, with strong bullish technical signals from moving averages. The stock shows extreme valuation metrics with P/S of 582.68 and negative profitability, though 100% of analysts maintain buy ratings with a $38.78 consensus target. Recent Q2 2026 results missed revenue expectations but showed a 1,120% surge in bookings, highlighting the speculative growth nature of this quantum computing play.
The outlook remains speculative with significant execution risk given negative cash flows and mounting losses, but potential exists if quantum computing adoption accelerates. Investors face high volatility amid ongoing operational losses despite strong analyst conviction and institutional interest in this emerging technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
